Remember Torax Medical? This is the company with the clever implantable magnet device called LINX® that was FDA cleared for use in resolving Gastro-Esophageal Reflux Disease (GERD) back in early 2012. Well, now the company is reporting the approaching completion of 5 year data collection in the clinical trial for the LINX procedure.
LINX is a small implant comprised of interlinked titanium beads with magnetic cores. The magnetic attraction between the beads augments the existing esophageal sphincter’s barrier function to prevent reflux. The device is implanted using a standard minimally invasive laparoscopic procedure and is an alternative to the more anatomically disruptive fundoplication, commonly used in surgical anti-reflux procedures. The LINX Reflux Management System is indicated for those patients diagnosed with GERD as defined by abnormal pH testing, and who continue to have chronic GERD symptoms despite maximum medical therapy for the treatment of reflux.
Previous reporting of safety and efficacy for this pivotal trial provided the scientific evidence necessary for FDA approval for the LINX device in early 2012. This was an IDE multi-center, prospective, pivotal trial, statistically powered to establish scientific evidence of safety and efficacy of the LINX procedure in the treatment of chronic reflux disease. Patients included in the pivotal trial were refractory to proton-pump inhibitor (PPI) therapy and had pathologic levels of esophageal acid exposure.
So to today and those 5 year figures, which yielded data relating to the control of reflux related symptoms and reduction in dependence of PPI therapy. Preliminary assessment of these endpoints, with over 80% of available patients reporting, showed that 86% of patients continue to have significant reduction in their reflux symptoms and 86% have eliminated their daily dependence on PPI therapy. These results are consistent with the 3-year clinical outcomes previously reported from this study in the New England Journal of Medicine.
Torax says this data, along with additional peer-reviewed publications, including a safety analysis of over 1,000 patients confirm the clinical benefits and safety of the LINX procedure.
“Completion of this pivotal trial is a momentous achievement for the study investigators. The vigilance necessary to perform a study of this magnitude is significant and critical for the advancement of minimally invasive surgery,” commented Dr. Tom R. DeMeester, Chairman of the Medical Advisory Board for Torax Medical and Chairman Emeritus, USC Department of Surgery. Dr. DeMeester further stated, “This new data provides an essential basis for the long-term durability of the LINX procedure. GERD is a chronic condition and needs a minimally invasive treatment option like LINX, when the disease becomes progressive.”
Todd Berg, President and CEO for Torax Medical said, “Torax Medical and physician thought leaders have now collaborated for over a decade building a foundation of evidence to support the safety and efficacy of the LINX procedure. Top U.S. medical journals have already reported on over 1,000 unique patients treated with the LINX procedure. This 5-year pivotal study is an excellent capstone to this effort. Today, we are excited to see the LINX procedure offered in more than 200 medical centers, and are expanding this number monthly as new centers complete the LINX training program.”
Source: Torax Medical, Inc., Business Wire